The role of therapeutic monitoring of everolimus in solid organ transplantation

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 666-676

  Mabasa, Vincent H ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Ridge Meadows Hospital and Health Care Centre   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Everolimus; Immunosuppressants; Solid organ transplantation; Therapeutic drug monitoring

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; AZITHROMYCIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; GEMFIBROZIL; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

AREA UNDER CURVE; DRUG MONITORING; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; SIROLIMUS;

EID: 26444567404     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000175911.70172.2e     Document Type: Review

References (40)

1. 2004 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network. Transplant Data 1989-2002. (2004, May 3). Rockville, MD and Richmond, VA: HHS/HRSA/OSP/DOT and UNOS.
2. Smith SL. Immunosuppressive therapies in organ transplantation [Medscape WebMD web site], June 25, 2002. Available at: http://www.medscape.com/ viewarticle/437182. Accessed April 19, 2005.
3. Nashan B. The role of Certican in the many pathways of chronic rejection. Transplant Proc. 2001;33:3215-3220.
4. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc. 2004;36:(Suppl 2S)500S-503S.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
6. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95.
7. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69:48-56.
8. Neumayer HH, Paradis K, Korn A, et al. Entry into human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol. 1999;48:694-703.
9. Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34:265-279.
10. Vitko S, Margreiter R, Weimar W, et al. Everolimus 12 month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004;78:11532-11540.
11. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001;71:1400-1406.
12. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal transplant recipients: a three year phase II, randomized, multicenter, open label study. Transplantation. 2004;78:1332-1340.
13. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4:626-635.
14. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med. 2003;349:847-858.
15. Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant. 2003;22:1117-1125.
16. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation. 2003;75:2082-2085.
17. Vester U, Kranz B, Wehr S, et al. Everolimus in combination with neural in pediatric renal transplant recipients: interim analysis after 3 months. Transplant Proc. 2002;34:2209-2210.
18. Salm P, Taylor PJ, Lynch SV, et al. Quantification and stability of everolimus in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B. 2002;772:283-290.
19. Baldelli S, Murgia S, Merlini S, et al. High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. J Chromatogr B. 2005;816:99-105.
20. Deters M, Kirchner G, Resch K, et al. Simultaneous-quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid-chromatography-mass spectrometry. Clin Chem Lab Med. 2002;40:285-292.
21. McMahon L, Luo S, Hayes M, et al. High throughput analysis of everolimus and cyclosporin A in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system. Rapid Commun Mass Spectrom. 2000;14:1965-1971.
22. Christians U, Jacobsen W, Serkova N, et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B. 2000;748:41-53.
23. Vidal C, Kirchner G, Wunsch G, et al. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection. Clin Chem. 1998;44:1275-1282.
24. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood. Clin Chem. 2002;48:955-958.
25. Segarra I, Brazelton TR, Guterman N, et al. Development of a high performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl) rapamycin. J Chromatogr B. 1998;720:179-187.
26. Brignol N, McMahon LM, Luo S, et al. High throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus and cyclosporine A in whole blood. Rapid Commun Mass Spectrom. 2001;15:898-907.
27. Svensson JO, Brattsrrom C, Sawe J. Determination of rapamycin in whole blood by HPLC. Ther Drug Monit. 1997;19:112-116.
28. Boudennaia TY, Napoli KL. Validation of a practical liquid chromatography with ultraviolet detection method for quantification of whole-blood everolimus in clinical TDM laboratory. Ther Drug Monit. 2005;27:171-177.
29. Strom T, Boyd J, Arabshahi L, et al. Cross-reactivity of the major everolimus hydroxy metabolites with the Innofluor® Certican® immunoassay for clinical TDM of everolimus [abstract]. Ther Drug Monit. 2005;27:243.
30. Engelmayer J, Engelmayer U, Streit F, et al. Comparison of the Seradyn Innofluor® Certican® assay on TDXFLX® system with LC/MS-MS [abstract]. Ther Drug Monit. 2005;27:217.
31. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced exposure cyclosporin in de novo kidney transplantation. Ther Drug Monit. 2004;26:499-505.
32. Young M, Plosker GL. Mycophenolatemofetil: a pharmacoeconomic review of its use in solid organ transplant. Pharmacoeconomics. 2002;20:675-713.
33. Holmes M, Chilcott J, Walters S, et al. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. Transpl Int. 2004;17:182-187.
34. Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther. 2001;70:247-254.
35. Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin Pharmacol Ther. 2001;70:425-430.
36. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant. 2004;4:2126-2131.
37. Kovarik JM, Kaplan B, Tedesco H, et al. Exposure-relationships for everolimus in de novo kidney transplantation. Transplantation. 2002;73:920-925.
38. Levy GA, Grant D, Paradis K, et al. Pharmacokinetics and tolerability of 40-O-[2-hydroxyethyl] rapamycin in de novo liver transplant recipients. Transplantation. 2001;71:160-163.
39. Kahan B, Wong R, Carter C, et al. A phase I study of a 4-week course of SDZ RAD in quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1999;68:1100-1106.
40. Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol. 2005;95:113-116.